# Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis

> **NCT06954597** · PHASE2 · RECRUITING · sponsor: **Topadur Pharma AG** · enrollment: 15 (estimated)

## Conditions studied

- Digital Ulcers in Systemic Sclerosis

## Interventions

- **DRUG:** TOP-N53
- **DRUG:** Sildenafil
- **DRUG:** TOP-N53 vehicle

## Key facts

- **NCT ID:** NCT06954597
- **Lead sponsor:** Topadur Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-04
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06954597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06954597, "Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06954597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*